# Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Source: https://onco.cc/trials/nct04041310/  
OnCo record `nct04041310` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Nouscom SRL, active and no longer recruiting.

## Summary

Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors is a phase 1/2 interventional study registered as NCT04041310 by Nouscom SRL, with 115 participants enrolled, started 2019-10-21 and due to reach its primary completion in 2026-10-30. Interventions recorded: GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D and MVA-209-FSP, RP2D.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04041310
- Phase: 1/2
- Setting: A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
- Sponsor: Nouscom SRL
- Enrolled: 115

## Sources

- ClinicalTrials.gov NCT04041310: https://clinicaltrials.gov/study/NCT04041310

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/), [Nouscom](https://onco.cc/companies/nouscom/)

---
JSON: https://onco.cc/api/v1/entities/nct04041310.json